<unk>  is a form of parathyroid hormone (PTH) consisting of the first (N-terminus) 34 amino acids, which is the bioactive portion of the hormone. It is an effective anabolic (promoting bone formation) agent used in the treatment of some forms of osteoporosis. It is also occasionally used off-label to speed fracture healing.<unk>  is identical to a portion of human parathyroid hormone and intermittent use activates osteoblasts more than osteoclasts, which leads to an overall increase in bone. Recombinant<unk>  is sold by Eli Lilly and Company under the brand name Forteo/Forsteo. On June 11, 2020, Alvogen, Inc, Pfenex Inc.'s commercialization partner, launched<unk>  injection (Bonsity) in the United States.<unk>  injection was developed by Pfenex Inc and approved by the US Food and Drug Administration (FDA) on October 4, 2019.<unk>  injection is pharmaceutically equivalent to Forteo (that is, has the same active ingredient in the same strength, dosage form and route of administration) and has been shown to have comparable bioavailability. These characteristics allowed the product to be approved under a 505(b)(2) NDA for which Forteo was the reference drug. It may provide a lower-cost<unk>  option for increasing bone density in patients at high risk for fracture, and is FDA-approved for the same indications as Forteo, which means it can be used for the same patients as Forteo, including new patients and those currently responding to treatment.<unk>  was approved for medical use in the European Union in June 2003. A synthetic<unk>  from Teva Generics has been authorised for marketing in the European Union. Biosimilar product from Gedeon Richter plc has been authorised in the European Union. On October 4, 2019, the US FDA approved a recombinant<unk>  product. In June 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of the biosimilar products Qutavina and Livogiva. Qutavina and Livogiva were approved for medical use in the European Union in August 2020.
Teriparatide
Denosumab
Bolazine capronate
Zoledronic acid
Medronic acid
Alendronic acid
Risedronic acid
Ibandronic acid